Top

Published in:

01-10-2003

Cancer prevention for working class, multiethnic populations through small businesses: the healthy directions study

Authors: Mary K. Hunt, Anne M. Stoddard, Elizabeth Barbeau, Roberta Goldman, Lorraine Wallace, Caitlin Gutheil, Glorian Sorensen

Published in: Cancer Causes & Control | Issue 8/2003

Title: Cancer prevention for working class, multiethnic populations through small businesses: the healthy directions study
Authors: Mary K. Hunt
Anne M. Stoddard
Elizabeth Barbeau
Roberta Goldman
Lorraine Wallace
Caitlin Gutheil
Glorian Sorensen
Publication date: 01-10-2003
Publisher: Kluwer Academic Publishers
Published in: Cancer Causes & Control / Issue 8/2003
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1023/A:1026327525701

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 8/2003

Residential and occupational exposure to 50 Hz magnetic fields and hematological cancers in Norway

Thyroid cancer pooled analysis from 14 case–control studies: what have we learned?

Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States)

Race, socioeconomic status and stage at diagnosis for five common malignancies

Intake of vitamins A, C, and E from diet and supplements and breast cancer in postmenopausal women

Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends

Keynote webinar | Spotlight on antibody–drug conjugates in cancer